Abionyx Pharma SA banner

Abionyx Pharma SA
LSE:0RAG

Watchlist Manager
Abionyx Pharma SA Logo
Abionyx Pharma SA
LSE:0RAG
Watchlist
Price: 3.535 EUR 2.61% Market Closed
Market Cap: €497.5k

Wall St Price Targets

0RAG Price Targets Summary
Abionyx Pharma SA

Wall Street analysts forecast 0RAG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 0RAG is 10.505 EUR with a low forecast of 9.906 EUR and a high forecast of 11.328 EUR.

Lowest Forecast
Price Target
9.906 EUR
180% Upside
Average Forecast
Price Target
10.505 EUR
197% Upside
Highest Forecast
Price Target
11.328 EUR
220% Upside
Abionyx Pharma SA Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
112% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
112% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

The compound annual growth rate for Revenue over the next 3 years is 112%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-42%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 0RAG's stock price target?
Price Target
10.505 EUR

According to Wall Street analysts, the average 1-year price target for 0RAG is 10.505 EUR with a low forecast of 9.906 EUR and a high forecast of 11.328 EUR.

What is the Revenue forecast for Abionyx Pharma SA?
Projected CAGR
112%

The compound annual growth rate for Revenue over the next 3 years is 112%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett